Work

初期経験的抗菌治療薬としてのカルバペネムによる重症患者の死亡率改善はなく、その使用期間と関連して多剤耐性菌の同定が増加する:前向きコホート研究の二次解析

Year: 2024
Type: dissertation
Abstract: Whether empirical therapy with carbapenems positively affects the outcomes of critically ill patients with bacterial infections remains unclear.This study aimed to investigate whether the use of carbapenems as the initial antimicrobial administration reduces mortality and whether the duration of carbapenem use affects the detection of multidrug-resistant (MDR) pathogens.This was a post hoc analysis of data acquired from Japanese participating sites from a multicenter, prospective observational study [Determinants of Antimicrobial Use and De-escalation in Critical Care (DIANA study)].A total of 268 adult patients with clinically suspected or con firmed bacterial infections from 31 Japanese intensive care units (ICUs) were analyzed.The patients were divided into two groups: patients who were administered carbape nems as initial antimicrobials (initial carbapenem group, n = 99) and those who were not administered carbapenems (initial non-carbapenem group, n = 169).The primary outcomes were mortality at day 28 and detection of MDR pathogens.Multivariate logistic regression analysis revealed that mortality at day 28 did not differ between the two groups [18 (18%) vs 27 (16%), respectively; odds ratio: 1.25 (95% confidence interval (CI): 0.59-2.65),P = 0.564].The subdistribution hazard ratio for detecting MDR pathogens on day 28 per additional day of carbapenem use is 1.08 (95% CI: 1.05-1.13,P < 0.001 using the Fine-Gray model with death regarded as a competing event).In conclusion, in-hospital mortality was similar between the groups, and a longer duration of carbape nem use as the initial antimicrobial therapy resulted in a higher risk of detection of new MDR pathogens. IMPORTANCEWe found no statistical difference in mortality with the empirical use of carbapenems as initial antimicrobial therapy among critically ill patients with bacte rial infections.Our study revealed a lower proportion of inappropriate initial antimicro bial administrations than those reported in previous studies.This result suggests the importance of appropriate risk assessment for the involvement of multidrug-resistant (MDR) pathogens and the selection of suitable antibiotics based on risk.To the best of our knowledge, this study is the first to demonstrate that a longer duration of carbape nem use as initial therapy is associated with a higher risk of subsequent detection of MDR pathogens.This finding underscores the importance of efforts to minimize the duration of carbapenem use as initial antimicrobial therapy when it is necessary.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7144707268
Cites: 40
Cited by:
Related to: 10